Vyvanse CII significantly improved ADHD symptoms for children 13 hours after administration
Wednesday, July 22, 2009 - 14:35
in Health & Medicine
PHILADEPHIA -- July 22, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse® (lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in chi